Replimune Group, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 64/100
What the filing says
Replimune priced an underwritten offering of 9,701,490 common shares at $12.06/share and pre-funded warrants for 2,736,340 shares at $12.0599/warrant ($0.0001 exercise price). Gross proceeds ~$150M. Underwriters: Leerink Partners, J.P. Morgan, Cantor. Closing expected August 11, 2026.
Why this rating
~$150M gross proceeds (64% of $234.5M market cap) materially strengthens cash position for biotech clinical programs. Significant dilution offsets upside.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.